• Andrew Kim, Joshua A Spiro, Thomas J Hatzidais, Norman D Randolph, Rosie Q Li, Diana Ayubcha, and Mark S Weiss.
• Department of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
• Curr Opin Anaesthesiol. 2021 Aug 1; 34 (4): 490-496.

Purpose Of ReviewThe incidence of obesity and the use of endoscopy have risen concurrently throughout the 21st century. Bariatric patients may present to the endoscopy suite for primary treatments as well as preoperatively and postoperatively from bariatric surgery. However, over the past 10 years, endoscopic bariatric and metabolic therapies (EBMTs) have emerged as viable alternatives to more invasive surgical approaches for weight loss.Recent FindingsThe United States Food and Drug Administration (FDA) has approved several different gastric EBMTs including aspiration therapy, intragastric balloons, and endoscopic suturing. Other small intestine EBMTs including duodenal mucosal resurfacing, endoluminal magnetic partial jejunal diversion, and Duodenal-Jejunal Bypass Liner are not yet FDA approved, but are actively being investigated.SummaryObesity causes anatomic and physiologic changes to every aspect of the human body. All EBMTs have specific nuances with important implications for the anesthesiologist. By considering both patient and procedural factors, the anesthesiologist will be able to perform a safe and effective anesthetic.Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

10 keywords...

hide…